新股消息 卓正医疗通过港交所聆讯 专注服务中高端医疗服务市场

Core Viewpoint -卓正医疗控股有限公司 is strategically focused on the mid-to-high-end medical service market in China, targeting affluent consumers with a preference for personalized healthcare services [1][2] Group 1: Company Overview -卓正医疗 is the third-largest private mid-to-high-end comprehensive medical service provider in China, with a market share of 2.0% based on 2024 revenue [1] -By 2025, the company will operate 19 medical service institutions across China, including 17 clinics and 2 hospitals, and has additional clinics in Singapore and Malaysia [2] -The company employs a family medicine model that integrates both physical and online healthcare services, enhancing patient satisfaction and facilitating cross-specialty referrals [2] Group 2: Market Dynamics -The total revenue of China's private mid-to-high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, representing a compound annual growth rate (CAGR) of 21.9% [2] -Private mid-to-high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in the mid-to-high-end medical service market in China by 2024 [1] Group 3: Financial Performance -卓正医疗's revenue has shown a consistent upward trend, with figures of RMB 473 million, RMB 690 million, and RMB 959 million for the years 2022 to 2024, respectively [3] -The company recorded net losses of RMB 222 million and RMB 353 million in 2022 and 2023, but achieved profits of approximately RMB 80.2 million and RMB 83.2 million in 2024 and the first eight months of 2025 [3] -The company has a team of 387 full-time doctors, with an average of 15 years of experience, and 79% of them previously worked in top-tier hospitals [3]